Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease

What Was Tested

The paper reports a study of Somatostatin and Pasireotide, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

Open-label treatment continued through month 12.

HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.

How the Study Was Run

In design terms this was a randomized, double-blind and open-label study.

The participants were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Somatostatin.

Everyone knew when Somatostatin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.

Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.

What Was Measured

Topics PubMed links to this paper include Pituitary ACTH Hypersecretion, Quality of Life and Somatostatin.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Somatostatin and Pasireotide.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (European journal of endocrinology), a journal based in England.

More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.